Morning Market Losers

shares tumbled 55.13 percent to $6.17 following U.S. regulatory update for migalastat monotherapy.

shares dipped 12.13 percent to $22.52. Progress Software reported stronger-than-expected earnings for its fiscal third quarter. However, the company reported downbeat quarterly revenue and lowered its revenue forecast for the full year. The company also announced a new $100 million buyback program.

shares fell 9.93 percent to $26.57. Morgan Stanley downgraded Diplomat Pharmacy from Overweight to Equal-weight and lowered the price target from $58 to $31.

declined 9.67 percent to $17.01 after the company reported topline results of CHS-1701 pharmacokinetic and pharmacodynamic biosimilarity study.

shares dropped 5.70 percent to $1.08 after the company reported that it has received second tranche of $3 million from Discover Growth Fund.

shares fell 2.87 percent to $45.99 after the company priced 10 million share offering at $46.88 per share.

shares declined 2.74 percent to $95.58. Morgan Stanley downgraded Gilead Sciences from Overweight to Equal-weight.